{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:11:18Z","timestamp":1770840678805,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,11]]},"DOI":"10.7759\/cureus.103430","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:28:11Z","timestamp":1770838091000},"source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia-Like Presentations Following PD-1 Inhibitors: CD8+ Myositis, Myasthenia, or Both?"],"prefix":"10.7759","author":[{"given":"Selen","family":"Ucem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulshan","family":"Yunisova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eser","family":"Bulus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahin","family":"Lacin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piraye","family":"Oflazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"13","author":"Albarr\u00e1n V","year":"2022","unstructured":"Albarr\u00e1n V, Chamorro J, Rosero DI, Saavedra C, Soria A, Carrato A, Gajate P. Neurologic toxicity of immune checkpoint inhibitors: a review of literature. Front Pharmacol. 2022, 13:774170. 10.3389\/fphar.2022.774170","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101192","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp L","year":"2025","unstructured":"Plomp L, Chassepot H, Psimaras D, et al.. Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. Lancet Reg Health Eur. 2025, 50:101192. 10.1016\/j.lanepe.2024.101192","journal-title":"Lancet Reg Health Eur"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103131","article-title":"Pathogenicity of functionally activated PD-1(+)CD8(+) cells and counterattacks by muscular PD-L1 through IFN\u03b3 in myositis","volume":"142","author":"Sasaki H","year":"2024","unstructured":"Sasaki H, Umezawa N, Itakura T, Iwai H, Yasuda S. Pathogenicity of functionally activated PD-1(+)CD8(+) cells and counterattacks by muscular PD-L1 through IFN\u03b3 in myositis. J Autoimmun. 2024, 142:103131. 10.1016\/j.jaut.2023.103131","journal-title":"J Autoimmun"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51761","article-title":"Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis","volume":"10","author":"Masi G","year":"2023","unstructured":"Masi G, Pham MC, Karatz T, et al.. Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis. Ann Clin Transl Neurol. 2023, 10:825-31. 10.1002\/acn3.51761","journal-title":"Ann Clin Transl Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01571-0","article-title":"Clinical issue of myasthenia gravis related to immune checkpoint inhibitors","volume":"26","author":"Kaira K","year":"2024","unstructured":"Kaira K, Mouri A, Imai H, Yamaguchi O, Kagamu H. Clinical issue of myasthenia gravis related to immune checkpoint inhibitors. Curr Oncol Rep. 2024, 26:1113-9. 10.1007\/s11912-024-01571-0","journal-title":"Curr Oncol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review","volume":"15","author":"Qin Y","year":"2024","unstructured":"Qin Y, Chen S, Gui Q, et al.. Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review. Front Neurol. 2024, 15:1372861. 10.3389\/fneur.2024.1372861","journal-title":"Front Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2512645","article-title":"A review of immune checkpoint inhibitor-associated myocarditis: epidemiology, pathogenesis, and biomarkers","volume":"21","author":"Xu L","year":"2025","unstructured":"Xu L, Chen Y, Xiong L, Shen Y, Zhou Z, Wang S, Xu X. A review of immune checkpoint inhibitor-associated myocarditis: epidemiology, pathogenesis, and biomarkers. Hum Vaccin Immunother. 2025, 21:2512645. 10.1080\/21645515.2025.2512645","journal-title":"Hum Vaccin Immunother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430825-myasthenia-like-presentations-following-pd-1-inhibitors-cd8-myositis-myasthenia-or-both","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:28:12Z","timestamp":1770838092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430825-myasthenia-like-presentations-following-pd-1-inhibitors-cd8-myositis-myasthenia-or-both"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.103430","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}